PLYX
Polaryx Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.00
+0.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expense | 2.5M | 6.3M | 2.8M | 2.8M |
| SG&A Expense | 2.8M | 1.6M | 1.5M | 1.0M |
| General & Admin Expense | 2.1M | 1.6M | 1.5M | 1.0M |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 5.2M | 7.8M | 4.4M | 3.8M |
| Cost and Expenses | 5.2M | 7.8M | 4.4M | 3.8M |
| Operating Income (EBIT) | (5.2M) | (7.8M) | (4.4M) | (3.8M) |
| Non-Operating | ||||
| Interest Income | — | — | — | — |
| Interest Expense | — | — | — | — |
| Net Interest Income | — | — | — | — |
| Other Non-Op Income/Expense | (1.6M) | (1.2M) | (26.0M) | 2.0K |
| Non-Operating Income (excl Interest) | 1.6M | 1.2M | 26.0M | (2.0K) |
| EBT (Pre-Tax Income) | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
| Income Tax Expense | — | — | — | — |
| Bottom Line | ||||
| Net Income | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
| Earnings from Cont. Ops | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
| Per Share | ||||
| Basic EPS | ($0.12) | ($0.19) | ($0.16) | ($0.02) |
| Diluted EPS | ($0.12) | ($0.19) | ($0.16) | ($0.02) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | ||||
| Basic Shares Outstanding | 48.3M | 47.3M | 189.4M | 189.4M |
| Diluted Shares Outstanding | 48.3M | 47.3M | 189.4M | 189.4M |
| Profitability Metrics | ||||
| EBITDA | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
| D&A | — | — | — | — |
| EBIT | (6.8M) | (9.0M) | (30.4M) | (3.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026